ArticleKidney international2013
JC polyoma virus interacts with APOL1 in African Americans with nondiabetic nephropathy.
Article in Kidney international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Genome-wide association studies suggest that APOL1-environment interactions more likely trigger kidney disease in African Americans with nondiabetic nephropathy than strong APOL1-second gene interactions.Kidney international · 2018Pooled it
- Examination of Potential Modifiers of the Association of APOL1 Alleles with CKD Progression.Clinical journal of the American Society of Nephrology : CJASN · 2015Trial
- Beyond Genotype: Multidomain Biomarker-Integrated Risk Scores Reveal Prognostic phenotypes Among Individuals with High-RiskmedRxiv : the preprint server for health sciences · 2026Article
- Apolipoproteins L involvement in immunity.Journal of human immunity · 2026Review
- APOL1-mediated kidney disease: a narrative review of the lessons learnt from the past 15 years.BMC nephrology · 2025Review
- A rationally designed injury kidney targeting peptide library and its application in rescuing acute kidney injury.Science advances · 2025Article
- Management of traditional risk factors for the development and progression of chronic kidney disease.Clinical kidney journal · 2023Review
- Virus-Associated Nephropathies: A Narrative Review.International journal of molecular sciences · 2022Review
- Urinary Tract Virome as an Urgent Target for Metagenomics.Life (Basel, Switzerland) · 2021Review
- APOL1 risk variants in kidney transplantation: a modulation of immune cell function.The Journal of clinical investigation · 2021Article
- APOL1 risk variants and the development of HIV-associated nephropathy.The FEBS journal · 2021Review
- APOL1 at 10 years: progress and next steps.Kidney international · 2021Article
- A focus on the association of Apol1 with kidney disease in children.Pediatric nephrology (Berlin, Germany) · 2021Review
- Diagnostic accuracy of semiquantitative point of care urine albumin to creatinine ratio and urine dipstick analysis in a primary care resource limited setting in South Africa.BMC nephrology · 2021Article
- Outcomes of Living Kidney Donor Candidates and Living Kidney Recipient Candidates with JC Polyomavirus and BK Polyomavirus Viruria.International journal of nephrology · 2021Article
- HIV Viremia Is Associated WithFrontiers in medicine · 2021Article
- Gender and Ethnic Disparities of Acute Kidney Injury in COVID-19 Infected Patients: A Literature Review.Frontiers in cellular and infection microbiology · 2021Review
- Nephropathy Progression in African Americans With a Family History of ESKD: Implications for Clinical Trials in APOL1-Associated Nephropathy.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2019Article
- JC Virus andKidney international reports · 2019Article
- Searching for Second Hits for the Development ofKidney international reports · 2019Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
15 authors at 1 institution in 1 country.
Funding
Abstract
Individuals with HIV infection and two apolipoprotein L1 gene (APOL1) risk variants frequently develop nephropathy. Here we tested whether non-HIV viral infections influence nephropathy risk via interactions with APOL1 by assessing APOL1 genotypes and presence of urine JC and BK polyoma virus and plasma HHV6 and CMV by quantitative polymerase chain reaction. We analyzed 300 samples from unrelated and related first-degree relatives of African Americans with nondiabetic nephropathy using linear and nonlinear mixed models to account for familial relationships. The four groups evaluated were APOL1 zero/one versus two risk alleles, with or without nephropathy. Urine JCV and BKV were detected in 90 and 29 patients, respectively, whereas HHV6 and CMV were rare. Adjusting for family age at nephropathy, gender, and ancestry, presence of JCV genomic DNA in urine and APOL1 risk alleles were significantly negatively associated with elevated serum cystatin C, albuminuria (albumin-to-creatinine ratio over 30 mg/g), and kidney disease defined as an eGFR under 60 ml/min per 1.73 m(2) and/or albuminuria in an additive (APOL1 plus JCV) model. BK viruria was not associated with kidney disease. Thus, African Americans at increased risk for APOL1-associated nephropathy (two APOL1 risk variants) with JC viruria had a lower prevalence of kidney disease, suggesting that JCV interaction with APOL1 genotype may influence kidney disease risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.